Saturday, 22 July 2023

Week 413 Review - Optibiotix continues to recover

A rare 2nd positive week in a row as OPTI:Optibiotix increased again, improving the deficit between cost and value by £1,962 to £131,436, and total portfolio value increased to £53,455.

Not a great week for some magic formula shares, with both IGG:IG Group and III:3i Group dropping 5% for no apparent reason.

OPTI:Optibiotix wins Share of the Week, which is a rare occurrence, with a 7% increase in one of my holdings, but that's my best one and is still down 40%. Most of my holdings are down between 75% and 90%.

Here's the ISA and shares portfolio after week 49 of year 8.

Weekly Change
Cash £251.55 +£11.92
Portfolio cost £87,354.57 +£0
Portfolio sell value
(bid price-commission)
£23,330.27 (-73.3%) +£1,287.46
Potential profits £123.52 -£14.30
Yr 8 Dividends £131.81 +£11.64
Yr 8 Interest £1.79 +£0.28
Yr 8 Profit from sales -£10,795.53 +£0
Yr 8 proj avg monthly profit -£946.95 (-19.2%) +£20.81
Total Dividends £11,900.73 +£11.64
Total Interest £1.79 +£0.28
Total Profit from sales £17,298.53 +£0
Average monthly cash profit £302.48 (6.1%) -£0.61
(Sold stocks profit + Dividends
- Fees / Months)
Compound performance 49% +0%

The £11 dividend was from WHR:Warehouse REIT, and 28p interest was a thrill. Portfolio value went up by £1,287 but is still 73% down, and potential profits dropped by £14. Long term performance of 6.1% is 4% down on target, but it doesn't really mean anything when the portfolio value has dropped so much.


A slight tick up but still in danger of needing to adjust the Y axis lower. 


It's nice to have been above the trend line for some time now, but not enough to change it's direction.

The SIPP looks like this after week 397 overall and week 33 of year 8.




Weekly Change
Cash £265.87
-£145.27
Portfolio cost £95,774.40
+£923.42
Portfolio sell value
(bid price - commission)
£29,181.43 (-69.5%) +£640.48
Potential profits £144.25
-£272.55
Yr 8 Dividends £220.93
+£0
Yr 8 Interest £3.49
+£0.88
Yr 8 Profit from sales -£9,597.85
+£222.31
Yr 8 proj avg monthly profit -£1,241.20 (-22.9%) +£69.01
Total Dividends £14,363.71
+£0
Total Interest £3.74
+£0.88
Total Profit from sales £10,835.90
+£222.31
Average monthly cash profit £263.36 (4.8%) +£1.77
(Sold stocks profit + Dividends
- Fees / Months)
Compound performance 37% +0%

I know I have vowed never to buy any more OPTI:Optibiotix shares, but I can't stand by while people hoover them up at these prices, so I did buy some more this week. I added £360 to my SIPP to go with some dividend cash and bought 5,407 shares at 9.14p costing £506.15.

Then I decided I couldn't be bothered waiting for NUM:Numis Corp to get taken over, as the share price has stagnated and there's only one small dividend to come. I sold my 374 shares for 332.5802p making £222.30 (21.7%) profit and liberating £1,231.90. I used that to buy 12,525 shares in OPTI:Optibiotix at 9.74p costing £1,231.89.

This caused potential profits to drop by £272 as III:3i Group dropped 5% to add to the cashing in of £222 profit. Value went up by £640.


Again a very slight tick up but a long, long way below the injection line.


This account has been bumping along the trend line rather than just above it.

The trading account looks like this after week 363 overall and week 51 of year 7.




Weekly Change
Cash£20.26
+£0
Portfolio cost£1,763.50
+£0
Portfolio sell value
(bid price - commission)
£944.15(-46.5%)+£34.57
Potential profits£0
+£0
Year 7 Dividends£0.00
+£0
Year 7 Interests£0.03
+£0
Year 7 Profit-£1,157.99
+£0
Yr 7 proj avg monthly profit-£98.33(-66.9%)+£1.97
Dividends£60.10
+£0
Interest£0.03
+£0
Profit from sales-£930.69
+£0
Average monthly cash profit-£10.39(-7.1%)+£0.03
(Sold stocks profit + Dividends
- Fees / Months)

The increase in OPTI:Optibiotix gave this a little boost, but we're still a long way from being able to sell anything.


Still looks pretty bad.


Below the trend line, which is bad.

I'm 2 weeks behind so on a bit of a catch-up, and eager to post this week and next because Week 415 has just been very interesting!

No comments:

Post a Comment